Immutep Ltd (IMM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Immutep Ltd (IMM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH81812D
  • |
  • Pages: 85
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Immutep Ltd (Immutep) is formerly known as Prima BioMed Ltd, is a biotechnology company that develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. The company provide products based on LAG-3 immune control mechanism which is active in the regulation of the T cell immune response. It develops IMP701, a blocking anti-LAG-3 antibody for cancer and is in phase I of its clinical trials; CVac, a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer; IMP761, a humanized monoclonal antibody that binds to LAG-3 and autoreactive T-cells as an agonist to reduce immune reactions in autoimmune diseases, and others. Immutep's IMP321 is in clinical development for the treatment of a range of cancer indications. The company collaborates with pharmaceutical and biotech companies for its research and development activities. It has operations in Australia, Germany and France. Immutep is headquartered in Sydney, New South Wales, Australia.

Immutep Ltd (IMM)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Immutep Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Immutep Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Immutep Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Immutep Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Immutep Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Immutep Ltd, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Immutep Enters into Agreement with Merck and Pfizer 12

Immutep Enters into Clinical Trial Collaboration and Supply Agreement with Merck 13

Prima BioMed Enters into Agreement with Cytlimic 14

WuXi Biologics to Partner with Prima Biomed 15

Prima BioMed to Enter into Agreement with Krankenhaus Nordwest 16

Immutep Enters into Development Agreement with Eddingpharm for ImmuFact IMP321 17

Licensing Agreements 18

Prima BioMed Enters Into Licensing Agreement With Neopharm For CVac 18

CoStim Pharma Enters into Licensing Agreement with Immutep 20

Sydys Enters into Licensing Agreement with Prima BioMed 21

Equity Offering 22

Immutep Raises USD4.9 Million in Rights Offering of Shares 22

Immutep to Raise USD5.4 Million in Private Placement of Shares 23

Prima BioMed Plans Public Offering of American Depository Shares 25

Prima BioMed Raises USD5 Million in Private Placement of ADSs 26

Prima BioMed Raises USD1.4 Million in Private Placement of Shares 28

Prima BioMed Raises USD1.14 Million in Private Placement of Shares 29

Prima BioMed Raises USD7.5 Million in Rights Offering of Shares 30

Prima BioMed Raises USD0.19 Million in Private Placement of Shares upon Exercise of Warrants 31

Prima BioMed Plans to Raise USD4 Million in Rights Offering of Shares 32

Prima BioMed to Raise USD1 Million in Private Placement of Shares 33

Prima BioMed Files Registration Statement For Public Offering Of American Depositary Shares For USD 60 Million 34

Prima BioMed Completes Second Tranche Of Private Placement Of Shares For USD 3 Million 35

Prima BioMed Completes Private Placement Of Shares For USD 1.3 Million 36

Prima BioMed Completes Private Placement Of Shares For USD 1 Million 37

Prima BioMed Completes Rights Offering Of Shares For USD 5.2 Million 38

Debt Offering 39

Prima BioMed to Raise USD11 Million in Private Placement of 3% Notes 39

Acquisition 40

Prima BioMed Acquires Immutep for USD28 Million 40

Immutep Ltd-Key Competitors 41

Immutep Ltd-Key Employees 42

Immutep Ltd-Locations And Subsidiaries 43

Head Office 43

Other Locations & Subsidiaries 43

Recent Developments 44

Corporate Communications 44

Aug 20, 2017: Prima BioMed Appoints Non-Executive Director to the Board 44

Government and Public Interest 45

Aug 30, 2017: Prima Biomed And Monash University Receive Funding Grant For Lag-3 Research Project 45

Aug 16, 2017: Prima Biomed Receives AUSD 1.3 Million Tax Refund From French Government 46

Product News 47

10/17/2017: IMP321 New Data Accepted for Presentation at the Society for Immunotherapy of Cancer 2017 Annual Meeting 47

08/16/2017: Prima BioMed Receives A USD 1.3 Million Tax Refund From French Government 48

07/09/2017: Prima BioMed Announces Approval for the Initiation of the 'INSIGHT' Clinical Trial 49

06/04/2018: Immutep Presentations at ASCO 50

06/04/2017: LAG-3Ig (IMP321) Demonstrates Positive Safety and Efficacy Qualities in Breast Cancer Clinical Trial 51

06/01/2017: Prima Biomed Announces Formation Of Clinical Advisory Board 52

03/15/2017: Prima BioMed Completes Recruitment for Second Patient Cohort in Melanoma Trial and Will Present at ICI Conference in Boston 53

02/24/2017: First Half 2017 Operational Update 54

01/31/2018: Immutep Announces Milestone Payment From Chinese Partner EOC Pharma 55

01/03/2017: Prima Announces New Product Candidate IMP761-A LAG-3 Agonist Antibody 56

Product Approvals 57

Jul 02, 2018: Immutep Submits Investigational New Drug (IND) Application With FDA 57

Nov 15, 2017: Eftilagimod Alpha (LAG-3Ig Or IMP321) Pre-IND Meeting With the FDA 58

Clinical Trials 59

Aug 07, 2018: Immutep announces that the TACTI-mel study has Completed patient recruitment 59

Jul 30, 2018: Immutep's Lag-3 immunostimulant product candidate, Efti, receives IND approval from U.S. FDA 60

Jun 19, 2018: Immutep: Mid-point of Patient Enrollment Reached in AIPAC Trial 61

May 30, 2018: Positive New Data from Ongoing TACTI-mel Study in Unresectable or Metastatic Melanoma Presented in Global Webcast 62

May 17, 2018: Immutep to Present Interim Results from TACTI-mel Clinical Trial in Global Webcast 63

May 04, 2018: Immutep to Present at 2018 ASCO Annual Meeting 64

Apr 03, 2018: Immutep Provides Update On eftilagimod alpha (efti or IMP321) 65

Mar 22, 2018: Updated TACTI-mel Data Presented at the Cambridge Healthtech Institute's Immuno-Oncology Summit 66

Mar 21, 2018: Immutep Commences Patient Dosing in Additional TACTI-mel Cohort 67

Mar 05, 2018: Immutep receives AUSD 686,704 R&D Tax Incentive 68

Feb 09, 2018: Outcome from DSMB Safety Review and Extension of TACTI-mel Phase I Clinical Trial 69

Nov 09, 2017: New Eftilagimod Alpha (LAG-3Ig or IMP321) Data for Presentation at the Society for Immunotherapy of Cancer 2017 Annual Meeting 70

Oct 31, 2017: Dr. Frederic Triebel Presented at the World Immunotherapy Congress 2017 71

Oct 19, 2017: Dr. Frederic Triebel Presenting at the World Immunotherapy Congress 2017 72

Jun 26, 2017: Prima BioMed provides clinical trial update on IMP321 73

May 17, 2017: Data From Prima BioMed AIPAC Clinical Trial to be Presented at 2017 ASCO Conference 74

Apr 19, 2017: Prima BioMed Receives Approval for Third Cohort of Phase I Melanoma Trial 75

Apr 12, 2017: Prima BioMed receives AUSD 492,144 Tax Refund from Australian Government 76

Jan 23, 2017: Prima Biomed To Present At 2nd Annual Cancer Immunotherapy Conference 77

Jan 20, 2017: Prima BioMed Commences Randomised Phase IIb Clinical Trial for IMP321 in Breast Cancer 78

Jan 12, 2017: Prima BioMed Commences Recruitment for Second Cohort of Melanoma Trial 79

Other Significant Developments 80

Aug 07, 2018: Immutep provides update on its clinical programs 80

Dec 12, 2017: Immutep: Operational Update 82

Nov 20, 2017: Change of company name from Prima BioMed Limited' to Immutep 83

Nov 20, 2017: Prima BioMed Changes its Name to Immutep 84

Appendix 85

Methodology 85

About GlobalData 85

Contact Us 85

Disclaimer 85

List of Figures

Immutep Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Immutep Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Immutep Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Immutep Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Immutep Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Immutep Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Immutep Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Immutep Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

List of Tables

Immutep Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Immutep Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Immutep Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Immutep Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Immutep Ltd, Deals By Therapy Area, 2012 to YTD 2018 9

Immutep Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Immutep Enters into Agreement with Merck and Pfizer 12

Immutep Enters into Clinical Trial Collaboration and Supply Agreement with Merck 13

Prima BioMed Enters into Agreement with Cytlimic 14

WuXi Biologics to Partner with Prima Biomed 15

Prima BioMed to Enter into Agreement with Krankenhaus Nordwest 16

Immutep Enters into Development Agreement with Eddingpharm for ImmuFact IMP321 17

Prima BioMed Enters Into Licensing Agreement With Neopharm For CVac 18

CoStim Pharma Enters into Licensing Agreement with Immutep 20

Sydys Enters into Licensing Agreement with Prima BioMed 21

Immutep Raises USD4.9 Million in Rights Offering of Shares 22

Immutep to Raise USD5.4 Million in Private Placement of Shares 23

Prima BioMed Plans Public Offering of American Depository Shares 25

Prima BioMed Raises USD5 Million in Private Placement of ADSs 26

Prima BioMed Raises USD1.4 Million in Private Placement of Shares 28

Prima BioMed Raises USD1.14 Million in Private Placement of Shares 29

Prima BioMed Raises USD7.5 Million in Rights Offering of Shares 30

Prima BioMed Raises USD0.19 Million in Private Placement of Shares upon Exercise of Warrants 31

Prima BioMed Plans to Raise USD4 Million in Rights Offering of Shares 32

Prima BioMed to Raise USD1 Million in Private Placement of Shares 33

Prima BioMed Files Registration Statement For Public Offering Of American Depositary Shares For USD 60 Million 34

Prima BioMed Completes Second Tranche Of Private Placement Of Shares For USD 3 Million 35

Prima BioMed Completes Private Placement Of Shares For USD 1.3 Million 36

Prima BioMed Completes Private Placement Of Shares For USD 1 Million 37

Prima BioMed Completes Rights Offering Of Shares For USD 5.2 Million 38

Prima BioMed to Raise USD11 Million in Private Placement of 3% Notes 39

Prima BioMed Acquires Immutep for USD28 Million 40

Immutep Ltd, Key Competitors 41

Immutep Ltd, Key Employees 42

Immutep Ltd, Subsidiaries 43

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Immutep Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17848
Site License
USD 500 INR 35695
Corporate User License
USD 750 INR 53543

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com